# Novartis India share price today (Novartis India Ltd, NSE: NOVARTIND)

> Novartis India share price today: ₹1,722.40 at the NSE close on 3 November 2026, up 98.4% in a year. Novartis India (NSE: NOVARTIND) is worth ₹4,254 crore, trades at a P/E of 43.5 and has closed between ₹768.80 and ₹2,393.15 over the past 52 weeks. > Novartis India Ltd's share price has risen faster than its earnings: +98.4% in a year, against −7.7% for earnings per share. NOVARTIND · Pharma - MNC bulk Drugs · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/novartis-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Slowing from a peak, from the last 12 quarters
- Price: ₹1,722.40 (+98.4% in a year)
- P/E: 43.5× (higher than 75% of the last 11 years)
- Revenue (Jun 2026): ₹104 Cr (+18.2% on a year ago)
- Profit (Jun 2026): ₹32.0 Cr (+14.3% on a year ago)
- Operating margin: 34.0% (+3.0 points on a year ago)
- ROCE: 16%, FY26
- ROIC: −11.7%, against a 12.0% cost of capital: −23.7 points

The main question: the share price moved +98.4% in a year while yearly earnings per share moved −7.7%. The difference came from the market paying a higher multiple. ## What is the Novartis India share price today? Novartis India Ltd's share price was ₹1,722.40 at the close on 3 November 2026. It has been rising for 31 weeks. That is 17.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹769 and ₹2,393, and at that close it sat 59% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 16 weeks in a row. Over the last 11 years the share price moved +172% while the NIFTY 500 moved +257%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Novartis India this quarter? 1. Best operating margin in 15 quarters Operating margin was 34% in the June 2026 quarter, against 31% a year earlier. 2. Profit grew again in the June 2026 quarter Profit was ₹32 crore, +14.3% on a year earlier (₹28 crore), after 2 quarters of decline. ## What are Novartis India's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Novartis India reported revenue of ₹104 crore, up 18.2% from ₹88.0 crore a year earlier, and a profit of ₹32.0 crore, up 14.3% from ₹28.0 crore. ### Novartis India results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹104 crore | ₹88.0 crore | +18.2% |
| Profit | ₹32.0 crore | ₹28.0 crore | +14.3% |
| Earnings per share | ₹13.05 | ₹11.19 | +16.6% |
| Operating margin | 34.0% | 31.0% | +3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Novartis India share price history? Novartis India closed at ₹1,722.40 on 3 November 2026, up 98.4% from ₹868.05 a year earlier (31 October 2025) and up 114.7% over five years. Its highest weekly close since February 2016 was ₹2,393.15 on 11 September 2026. ### Novartis India share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,834.75 | −6.1% |
| 1 month ago · 1 Oct 2026 | ₹1,967.85 | −12.5% |
| 6 months ago · 30 Apr 2026 | ₹1,032.90 | +66.8% |
| 1 year ago · 31 Oct 2025 | ₹868.05 | +98.4% |
| 3 years ago · 3 Nov 2023 | ₹652.60 | +163.9% |
| 5 years ago · 4 Nov 2021 | ₹802.15 | +114.7% |
| 10 years ago · 4 Nov 2016 | ₹670.40 | +156.9% |
| Earliest weekly close in our records · 26 Feb 2016 | ₹634.00 | +171.7% |
| Highest weekly close since February 2016, also the 52-week high · 11 Sep 2026 | ₹2,393.15 | −28.0% |
| Lowest weekly close since February 2016 · 27 Mar 2020 | ₹459.30 | +275.0% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹768.80 | +124.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (565 weekly closes from 26 February 2016 to 3 November 2026.)

## What is the latest news on Novartis India? 3 Nov 2026: Novartis India closed at ₹1,722.40, down 6.1% on the week and down 12.5% on the month. Results for April to June 2026: Revenue up 18.2% and profit up 14.3% on a year earlier. ## What dividend does Novartis India pay? Novartis India paid no dividend in the 12 months to 4 November 2026. The last was a dividend + special dividend of ₹47.50 a share, ex-date 20 July 2023. ### Novartis India dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 20 Jul 2023 | ₹47.50 | Dividend + Special |
| 20 Jul 2022 | ₹10 | Dividend |
| 17 Aug 2021 | ₹10 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 3 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Novartis India Ltd paid out 66% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Novartis India on? Novartis India is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 4241.472642401323](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Novartis India profitable? Novartis India Ltd earned ₹32.0 Cr of net profit in the Jun 2026 quarter, +14.3% on the same quarter a year earlier. Full-year FY26 profit was ₹93.0 Cr. Over 10 years profit has grown −7.3% a year on average. That is 30.8% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr. For the full year, FY26 profit was ₹93.0 Cr (−7.9% on the year before). Why profit moved: revenue changed +18.2% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −3.9% and revenue +5.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Novartis India make, and is it growing? Novartis India Ltd reported ₹104 Cr of revenue in the Jun 2026 quarter, +18.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown −6.5% a year on average. The last full year, FY26, came in at ₹354 Cr. The last four reported quarters add to ₹371 Cr. FY26 revenue was ₹354 Cr, −0.6% on the year before. Recent pace: the last four quarters grew +5.6% on average, against −6.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.4%, against +4.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −4.9%, against +2.7% a year (rolling over). ## How much of every ₹100 of sales does Novartis India keep? Novartis India Ltd's operating margin was 34.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −1.1% and 27.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +2.5 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Novartis India's profit turning into cash? Over the last 3 years, 84% of Novartis India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹47.0 Cr of operating cash against ₹93.0 Cr of profit. After ₹0.0 Cr of spending on assets, ₹47.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 84% of profit came in as cash: the cash cycle got 17 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: it has been selling more assets than it buys. The next section shows those figures. ## Where does Novartis India's cash go? Novartis India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 36 days in FY26, up from 19 days in FY21. Over the last 3 years it sold more assets than it bought, by ₹9.0 Cr. Customers take 38 days to pay, and stock sits for 98 days on average. At FY26 sales of ₹354 Cr, each day of that cycle ties up about ₹1.0 Cr, so roughly ₹35.0 Cr is tied up in the business at any time. FY26: customers took 38 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of 36 days, longer than FY21's 19. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 38 days after that. Suppliers are paid at 101 days. Together that makes the 36-day cycle. Over the last 3 years, money from selling assets was ₹9.0 Cr more than it spent on new ones. Work still in progress is ₹0.0 Cr (FY26). In short: assets are being sold, not built, so this cash is not going into new capacity. ## What is Novartis India's P/E ratio, and how does it compare with its own history? Novartis India Ltd's P/E is 43.5×, near the high end of its own history: higher than 75% of past readings. Its usual P/E (the middle reading) is 30.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −7.7% while the price moved +98.4%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +16.5% a year; about +33.8% a year came from earnings growth and about −17.3 percentage points from the multiple (the market paying less); over 10 years the price moved +9.9% a year; about −1.0% a year came from earnings growth and about +10.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Novartis India business getting better or worse? Novartis India Ltd's business is slowing from a peak. Profit and EPS growth have slowed sharply (profit growth from +45.3% at its peak to −4.9% now), while ROCE is still 16.7%. This is based on 12 quarters of 4 measures. Why it matters: slowing from a peak is where good stories often end quietly. ## How much does Novartis India earn on its capital? Novartis India Ltd earned a ROCE of 16% in FY26. That is up from a low of 5% in FY20. Its return on capital used (ROIC) is 23.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 26.3% net margin and 0.36× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 26.3% net margin × 0.36× asset turnover × 1.20× leverage (assets divided by equity) ≈ 11.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −11.7% − 12.0% = −23.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −11.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 42.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Novartis India have too much debt? Novartis India Ltd has total debt of ₹3.0 Cr against shareholder equity of ₹818 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Novartis India shareholding pattern? Foreign institutions raised their stake in Novartis India Ltd by 1.0 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 1.2% of the company. Domestic institutions moved +1.0 points over the same period, to 1.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +1.0 points over 8 quarters, to 1.2%; Domestic institutions: +1.0 points over 8 quarters, to 1.5%; Promoters: +0.0 points over 8 quarters, to 70.7%. Why the owners changed: foreign institutions drove it (+1.0 points), together with domestic institutions (+1.0 points). They raised their stake step by step. ## How far is Novartis India from balance-sheet trouble? For Novartis India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Novartis India rank in its industry? 45.6 out of 100, rank 7 of 8 in Pharma - MNC bulk Drugs, with 96% of the evidence available. Novartis India Ltd scores 45.6 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 7. Relative strength against the index is 41.9%, and revenue and profit growth are weak. The four parts add up to the total exactly: 15.2 + 8.1 + 5.6 + 16.7 = 45.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Novartis India compared with? Novartis India ranks 7 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 45.6 out of 100. 1. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) GLAXO · losing its lead · Evidence leans up · 96% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.1/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.1 + 6.4 + 15.2 = 58.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) PFIZER · quiet · Evidence leans up · 96% evidence 52.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.7/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.7 + 19.6 + 3.4 = 52.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Novartis India Ltd this page NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Novartis India in size? Novartis India is the 8th largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Glaxosmithkline Pharmaceuticals, Pfizer, Astrazeneca Pharma India, Procter & Gamble Health, Sanofi Consumer Healthcare India and Sanofi India. It is the smallest. ### Pharma - MNC bulk Drugs companies close in size

1. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) ₹42,255 crore
2. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹16,871 crore
3. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
4. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) ₹9,413 crore
5. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) ₹7,928 crore
6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) ₹7,379 crore
7. Novartis India Ltd ₹4,179 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [Sanathan Textiles Ltd](https://www.sectoralpha.in/stocks/sanathan-textiles-ltd) ₹4,189 crore · Textiles - Spinning
2. [IFB Industries Ltd](https://www.sectoralpha.in/stocks/ifb-industries-ltd) ₹4,181 crore · Domestic Appliances
3. Novartis India Ltd ₹4,179 crore
4. [Universal Cables Ltd](https://www.sectoralpha.in/stocks/universal-cables-ltd) ₹4,176 crore · Cables - Power
5. [Datamatics Global Services Ltd](https://www.sectoralpha.in/stocks/datamatics-global-services-ltd) ₹4,163 crore · IT - Software

## What else do people ask about Novartis India? ### What is Novartis India's share price today? Novartis India Ltd's share price is ₹1,722.40, +98.4% over the past year. The whole company is worth ₹4,254 Cr on the market. In the last 52 weeks it traded between ₹769 to ₹2,393; today it is 59% of the way up from the low, 17.9% above its 200-day average (as of 3 November 2026). ### What were Novartis India's latest quarterly results? Novartis India Ltd reported revenue of ₹104 Cr and net profit of ₹32.0 Cr for the Jun 2026 quarter. Revenue rose 18.2% and profit rose 14.3% compared with a year earlier. Earnings per share were ₹13.05. The operating margin was 34.0%, 3.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Novartis India's market cap? Novartis India Ltd's market capitalisation is ₹4,254 Cr at a share price of ₹1,722.40. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Novartis India performing? Novartis India Ltd's share price has been rising for 31 weeks. In its latest quarter, revenue rose 18.2% and profit rose 14.3% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 16 weeks running (as of 3 November 2026). ### Will Novartis India's share price go up? This page does not forecast Novartis India Ltd's share price. What it shows instead: the share price is ₹1,722.40, and it has been rising for 31 weeks. Its P/E of 43.5× is higher than 75% of its own last 11 years (as of 3 November 2026). ### Who owns Novartis India? Promoters own 70.7% of Novartis India Ltd, foreign institutions 1.2%, domestic institutions 1.5% and the public 26.6% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.0 percentage points over 8 quarters (as of 3 November 2026). ### Does Novartis India have too much debt? No, Novartis India Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 94 times its interest bill. FY26 borrowings were ₹3.0 Cr against equity of ₹817 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### What is Novartis India's capex? Novartis India Ltd sold more long-term assets (plants, machines and the like) than it bought over the last 3 years, by ₹9.0 Cr, worked out from the change in fixed assets plus depreciation. Depreciation over the same years was ₹7.0 Cr (as of 3 November 2026). ### Where is Novartis India in its business cycle? Novartis India Ltd's FY26 operating margin was 27.0%, against a 13-year range of −1.1% to 27.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 34.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Novartis India story? The main question: the share price moved +98.4% in a year while yearly earnings per share moved −7.7%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Novartis India a stock worth studying right now? What the numbers show: Novartis India Ltd's share price has risen faster than its earnings: +98.4% in a year, against −7.7% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.